Key points are not available for this paper at this time.
Design
Editorial
The introduction of highly sensitive troponin assays may increase the diagnosis of myocardial infarction, potentially impacting critical illness insurance claims.
An elevated cardiac troponin is a sine qua non for the clinical diagnosis of myocardial infarction. The sensitivity of troponin assays has improved repeatedly since troponin entered clinical use in the late 1990s. Its most recent iteration, "highly sensitive" troponin will shortly enter clinical use in North America. It is able to detect amounts of troponin 10 times smaller than the current assay. As a result, more myocardial infarctions will be diagnosed. This may have an impact on the number of critical illness claims for heart attack.
No takes yet. Share an insight, caveat, or question.
Senn et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: